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Abstract
Introduction: Acute kidney injury following surgery incurs significant mortality with no proven preventative
therapy. We investigated whether the a2 adrenoceptor agonist dexmedetomidine (Dex) provides protection
against ischemia-reperfusion induced kidney injury in vitro and in vivo.
Methods: In vitro, a stabilised cell line of human kidney proximal tubular cells (HK2) was exposed to culture
medium deprived of oxygen and glucose. Dex decreased HK2 cell death in a dose-dependent manner, an effect
attenuated by the a2 adrenoceptor antagonist atipamezole, and likely transduced by phosphatidylinositol 3-kinase
(PI3K-Akt) signaling. In vivo C57BL/6J mice received Dex (25 μg/kg, intraperitoneal (i.p.)) 30 minutes before or after
either bilateral renal pedicle clamping for 25 minutes or right renal pedicle clamping for 40 minutes and left
nephrectomy.
Results: Pre- or post-treatment with Dex provided cytoprotection, improved tubular architecture and function
following renal ischemia. Consistent with this cytoprotection, dexmedetomidine reduced plasma high-mobility
group protein B1 (HMGB-1) elevation when given prior to or after kidney ischemia-reperfusion; pretreatment also
decreased toll-like receptor 4 (TLR4) expression in tubular cells. Dex treatment provided long-term functional
renoprotection, and even increased survival following nephrectomy.
Conclusions: Our data suggest that Dex likely activates cell survival signal pAKT via a2 adrenoceptors to reduce
cell death and HMGB1 release and subsequently inhibits TLR4 signaling to provide reno-protection.
Introduction
Perioperative acute kidney injury (AKI) is an abrupt dete-
rioration of renal function that occurs as a complication
of major cardiothoracic, vascular and transplant surgery
[1-5]. In this setting AKI is associated with prolonged
hospitalization and mortality rates as high as 60% [6,7];
including a 25-fold increase in mortality following car-
diac valve surgery [7,8]. Furthermore, patients who sus-
tain AKI and make a full recovery retain a higher risk of
long-term mortality [9].
Among its diverse etiologic factors, ischemia-reperfusion
injury (IRI) remains the foremost cause of perioperative
AKI [10]. Following a transient deprivation of total or
regional vascular supply to the kidney, restoration of blood
flow inflicts continuous and severe damage in the post-
ischemic renal parenchyma, characterized histopathologi-
cally as vascular, tubular, and inflammatory perturbations
[11]. A growing body of evidence demonstrates that the
TLR family, particularly TLR-4, plays the dominant role in
mediating the deleterious effects in renal IRI [12,13]. In
addition, damage-associated molecules such as HMGB-1
have been postulated as a TLR-4 ligand that drives the
robust inflammatory response in post-ischemic kidney
[14,15].
The current clinical management of perioperative AKI
is supportive [16]; therefore, novel prophylactic (pre-
insult therapy) and therapeutic (post-insult therapy) is
required to reduce the burden of AKI in the perioperative
period. The a2 adrenoceptor agonist dexmedetomidine
exerts sedative, analgesic, hemodynamic stabilizing, anti-
inflammatory and diuretic effects [17]. It is a highly
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specificity for the a2 adrenoceptor. Novel organoprotec-
tive properties of dexmedetomidine have been explored
in the brain, heart and renal injury [18-21]. Indeed a2
adrenoceptors are distributed widely in the renal proxi-
mal, distal tubules and peri-tubular vasculature. Clinically
a2 adrenoceptor agonists enhance urine flow rate and
perioperative renal function [22,23]; however, the under-
lying molecular mechanisms remain unknown. Animal
studies have suggested that a2 adrenoceptor agonists are
renoprotective as a class; their mechanism largely revol-
ving around modulating vasoreactivity [21,24,25]. Herein
we report that dexmedetomidine protects against IRI to
t h ek i d n e yi nm i c ea n dt h a tt h em e c h a n i s mi sd u et oa
decrease in the level of renal cell death and suppression
in the HMGB-1-TLR-4 inflammatory circuit.
Materials and methods
Cell line
A stabilised cell line of kidney cells (HK2), derived from
adult human kidney proximal tubular cells, was used in
our experiments (European Cell Culture Collection, Sal-
isbury, UK). Cells were cultured in RPMI 1640 medium,
1% L-glutamine 100 nM, 1% penicillin-streptomycin
100 U/ml, 5% fetal calf serum (Gibco, Invitrogen Ltd,
Paisley, UK) in a humidified atmosphere containing
5% CO2. They were used soon after reaching 80%
confluence.
Cell treatments
Cell injury was provoked by oxygen glucose deprivation
(OGD) as we reported previously [26]. Briefly, OGD solu-
tion (116 mM NaCl, 5.4 mM KCl, 0.8 mM MgSO4,
1.0 mM NaH2PO4,2 6m MN a H C O 3 and 1.8 mM CaCl2;
pH 7.4) was bubbled through with pure nitrogen gas for
15 minutes using sterile Drechsel bottles to remove oxy-
gen from the solution. Cells were washed sequentially
with warmed HEPES buffer solution (120 mM NaCl,
5.4 mM KCl, 0.8 mM MgCl2,1 . 8m MC a C l 2,1 5m M
anhydrous D-glucose and 20 mM HEPES) and warmed
prepared OGD solution. The multi-well plates were then
cultured with 1 ml of warmed OGD solution and incu-
bated in air tight gas chambers for the indicated period
e x p o s e dt o9 5 %n i t r o g e n ,5 %C O 2 at 37°C with or with-
out dexmedetomidine (0.001 to 0.1 nM) (Orion Pharm
(UK) Ltd, NewburyBerkshire, UK)+/- atipamezole
(1 nM). After OGD treatment, cells were removed from
the gas chamber, the OGD solution was replaced with
warmed culture medium and placed in a humidified 5%
CO2 incubator at 37°C for 24 hrs. Cell viability was
assessed using an 3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphe-
nyl-2H-tetrazolium bromide (MTT, Merck KGaA, Darm-
stadt, Germany) assay [26].
Other cell cohorts were treated with dexmedetomidine
(0.1 nM) in the absence of OGD with or without the
highly selective inhibitors of PI3-Akt, LY294002 (50 μM),
and mitogen-activated protein kinase (MAPK), PD98059
(50 μM), respectively.
Animals
Ten-week-old male C57BL/6J mice weighing 20 to 25 g
were housed in temperature and humidity-controlled
cages with free access to sterile acidified water and irra-
diated food in a specific pathogen-free facility at Imperial
College London. This study was approved by the ethics
committee of Imperial College London and the UK
Home Office (PPL: 70/6966) and all procedures were
performed strictly under the United Kingdom Animals
(Scientific Procedures) Act 1986.
Renal ischemia-reperfusion injury
Dexmedetomidine (25 μg/kg, i.p., based on the previous
organ protection studies [19,27]) was administered 30 min-
utes before or immediately after renal ischemia-reperfu-
sion injury (rIRI). One cohort was treated with the a2
adrenoceptor antagonist atipamezole (250 μg/kg, i.p.
[19,27]) prior to the administration of dexmedetomidine.
The naive group and the rIRI group served as negative
and positive controls, respectively. The animals were sacri-
ficed 24 hr after rIRI. Kidneys were harvested for H&E
and terminal deoxynucleotidyl transferase dUTP nick end
labeling (TUNEL) staining. All assessments were made by
an investigator who was blinded to the experimental pro-
tocols. rIRI was induced either by bilateral renal pedicle
clamping for 25 minutes to produce moderate renal injury,
or by right renal pedicle clamping for 40 minutes and left
nephrectomy to produce life-threatening renal injury,
under 1.5% isoflurane surgical anesthesia. Sham-operated
mice had dissection as above, but with no occlusion of the
renal vessel. The intra-abdominal temperature was main-
tained at 36 ± 0.1°C with a heating pad which was servo-
adjusted by a temperature controller (Engineering Inc,
Stamford, CT, USA) throughout the experiment. For sur-
vival experiments, mice were monitored on a daily basis
with a scoring assay based on body weight, activity and
general appearance as reported previously. Any animals
that scored > 7 were euthanized. All animals received
0 . 5m ls a l i n ei . p .i n j e c t i o np e re v e r y6h r sf o rt h ef i r s t
24 hrs after experiments.
Immunoblot
Proteins were extracted from treated HK2 cells lines or
frozen kidney samples by cell disruption in cell lysis buf-
fer (New England Biolabs, Hitchin, Hertfordshire, UK)
and sonication with an ultrasonic probe, followed by
centrifugation at 10,000 g for 10 minutes at 4°C. The
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containing 30 μg of extracted protein, as determined by
the Bradford protein assay (BioRad, Hemel Hempstead
Hertfordshire, UK), were loaded on a NuPAGE 4 to 12%
Bis-Tris gel (Invitrogen, Paisley, UK) for protein fractio-
nation by electrophoresis and then electro-transferred to
a nitrocellulose membrane (Hybond ECL; Amersham
Biosciences, Little Chalfont, Buckinghamshire, UK).
Blots were blocked with 5% non-fat dry milk in TBS
(pH8.0, containing 0.1% Tween-20), and probed with
appropriate antibodies (1:1,000 Akt, p-Akt and TLR4-
all from followed Cell Signaling, Hitchin, Hertfordshire,
UK; 1:100 TLR4- Santa Cruz, Wembley Middlesex, UK)
by HRP-conjugated secondary antibodies (Cell Signaling)
and visualisation with enhanced chemiluminescence
(Cell Signaling). a-tubulin (1:2,000, Sigma, Dorset, UK)
was used as internal control. Densitometry analysis were
preformed and normalized with a-tubulin and then pre-
sented as percentage of control.
Histologic score
The sum score was calculated from the analysis of 10 cor-
tical tubules/cross-section stained with H&E (10 sections/
kidney) by using a modified scoring system [28]; 0, no
d a m a g e .1 ,m i l dd a m a g e :r o u nded epithelial cells and
dilated tubular lumen; 2, moderate damage: flattened
epithelial cells, loss of nuclear staining and substantially
dilated lumen; 3, severe damage: destroyed tubules with
no nuclear staining of epithelial cells.
Immunohistochemistry
The second l death of tubular epithelial cells was detected
by in situ TUNEL assay Obiogene, Cambridge, UK)
according to the manufacturer’si n s t r u c t i o n s .T h ef i x e d
cryostat sections were washed with PBS and then treated
with proteinase K (20 μg/ml) at room temperature for
15 minutes. For positive controls, sections were treated
with nuclease (R&D System, Abingdon, UK) at 37°C for
15 minutes. The sections were quenched in 3% hydrogen
peroxide in PBS for five minutes. The quenched sections
were labelled with TDT enzyme at 37°C for 1 hour in a
humidified chamber and subsequently incubated with
anti-digoxygenin conjugated to horseradish peroxidase for
30 minutes at room temperature. They were then stained
with DiAminoBenzidine (DAB). The sum of the TUNEL
+
cells in an objective grid from 10 areas of randomly
selected renal cortex was counted under a 40 × objective
lens by an investigator who was blinded to the experimen-
tal protocol.
The other fixed cryostat sections were incubated with
3% hydrogen peroxide for 30 minutes to quench endogen-
ous peroxidase activity. Sections were blocked for 30 min-
utes in wash buffer phosphate buffered saline tween-20
containing 3% goat serum and then incubated at 4°C
overnight with goat anti-mouse TLR-4 (Santa Cruz Bio-
technology, Wembley, Middlesex, UK) diluted 1:250 in
PBS and 1% goat serum. After washing with PBST, sec-
tions were incubated with biotinylated donkey anti-goat
IgG (Santa Cruz) diluted 1:250 in PBS and then labelled
with VectaStain Elite ABC solution (Vector Labs, Orton
Southgate, Peterborough, UK). After further washes in
PBS, staining was developed with DiAminoBenzidine
(DAB) with nickel. Slides were washed in PBS buffer,
dH20 and then in 100% ethanol for 10 minutes and xylene
for 10 minutes before covered with cover glass for micro-
graph taken.
Plasma creatinine, urea and HMGB1
Both creatinine and urea were measured in 100 μlo f
plasma with an Olympus AU640 analyzer (Diamond Diag-
nostics, Watford, UK). Plasma HMGB1 was measured by
ELISA according to the manufacturer’s instruction (IBL
International GmbH, Hamburg, Germany)
Statistical analysis
Statistical comparison was by ANOVA followed by post
hoc Student-Newman Keul’s test where appropriate.
Survival was analyzed by Kaplan-Meier test. A P <0 . 0 5
was considered as statistically significant.
Results
Dexmedetomidine confers in vitro protection via Akt
activation
To determine whether dexmedetomidine provides reno-
protection in vitro, we exposed HK2 cells, a well-character-
ized human kidney proximal tubular cell line to oxygen and
glucose deprivation (OGD), established to mimic the
ischemic phase of renal ischemic reperfusion injury in our
previous studies [26]. Cell viability analysis using MTT
assay showed a time-dependent induction of injury with
marked cell death (60% reduction in viability) occurring
after 180-minutes OGD (0.39 ± 0.07 versus 1.0 ± 0.04 of
control; P < 0.05) and was, therefore, used in subsequent
experiments to determine the cytoprotective effects of
dexmedetomidine (Figure 1A).
Incubating HK2 cells with dexmedetomidine (0.001 to
0.1 nM) before OGD exposure dose-dependently inhibited
injury (Figure 1B). Treatment with 0.1 nM dexmedetomi-
dine increased cell viability to 94% (from 0.35 ± 0.10 to
0.94 ± 0.12; P < 0.05), compared with the positive control
(OGD). The cytoprotective effect of dexmedetomidine was
abolished by co-treatment with the a2 adrenoceptor
antagonist, atipamezole (1 nM), suggesting dexmedetomi-
dine confers protection to renal epithelial cells via a2 adre-
noceptor activation. Treatment of naïve controls with
either dexmedetomidine (0.1 nM) or atipamezole (1 nM)
did not significantly decrease cell viability (0.8 ± 0.13 and
1.0 ± 0.25 respectively versus control). Therefore, neither
Gu et al. Critical Care 2011, 15:R153
http://ccforum.com/content/15/3/R153
Page 3 of 11dexmedetomidine nor atipamezole were cytotoxic to HK2
cells.
Activation of the Akt pathway plays a key role in cyto-
protective signaling and has been demonstrated to ame-
liorate renal injury in IRI mice [29]. To determine
whether dexmedetomidine activates Akt, we measured
phosphorylated Akt (pAkt) levels in HK2 cells incubated
with media containing 0.1 nM dexmedetomidine for 5,
10, 20, 30 and 45 minutes (Figure 2A). Dexmedetomidine
induced significant increases in pAkt at all time-points;
whereas, total Akt protein levels were not altered. The
magnitude of Akt phosphorylation peaked after 20 min-
utes (2.91 ± 0.54 versus 1.0 ± 0.25 of control; P <0 . 0 1 )
and was used in subsequent experiments to identify
upstream mediators of Akt activation. Atipamezole
reduced, but could not completely abolish dexmedetomi-
dine-induced phosphorylation of Akt, suggesting that
pAkt activation may be partially dependent on a2 adre-
noceptors (Figure 2B). LY294002 and PD98059 have
been shown to act in vivo as highly selective inhibitors of
PI3-Akt and mitogen-activated protein kinase (MAPK)
cascades respectively. LY294002 (50 μM) rather than
PD98059 (50 μM) completely abolished dexmedetomi-
dine-induced activation of Akt (0.6 ± 0.2 versus 1.7 ± 0.2
of Dex only; P < 0.01), indicating that pAkt was generated
in a PI3K-dependent manner.
Dexmedetomidine reduces IRI pathological changes
in vivo
Next, we investigated whether dexmedetomidine pro-
vides protection against renal IRI in mice when the renal
pedicle of both kidneys are clamped for 25 minutes.
Twenty-four hours after IRI, kidneys and blood were har-
vested for histological assessment and for renal function
(serum creatinine and urea), respectively. Histopathologi-
cal assessment of cortical tubular damage was conducted
by an investigator blinded to the experimental protocol.
IRI significantly increased histopathological scoring
(151 ± 45 versus 19 ± 9 of naive control; P < 0.01), as illu-
strated by severe tubular lumen dilatation, flattened renal
epithelial cells and loss of nuclear staining (Figure 3C).
Pre- and post-treatment with dexmedetomidine (25 μg/
kg) resulted in a 53% and 38% reduction in damage (72 ±
15; P < 0.01 and 94 ± 19; P < 0.05) compared with IRI
group, respectively (Figure 3G). Atipamazole (250 μg/kg)
given prior to dexmedetomidine pre-treatment signifi-
cantly inhibited the reno-protective action (142 ± 38; P <
0.01). Treatment of naïve animals with dexmedetomidine
had no deleterious effects on kidney tissue (11 ± 9 versus
19 ± 9 of naïve control), in agreement with in vitro
findings.
To evaluate kidney damage at the cellular level, we used
terminal deoxynucleotidyl transferase-mediated digoxigen-
indeoxyuridine nick-end labeling (TUNEL) staining to
detect dead tubular cells. IRI significantly increased
TUNEL-positive cells (85.0 ± 28.5 versus 6.2 ± 5.3 of naive
control, P < 0.01). Pre- and post-treatment with dexmede-
tomidine resulted in a 72% and 58% reduction in
cell death (23.8 ± 7.5 and 35.2 ± 18.2; both P < 0.01), com-
pared to IRI mice, respectively (Figure 4). Cellular reno-
protection was abolished when dexmedetomidine
pre-treatment was preceded by atipamazole (89.0 ± 14.3;
Figure 1 Renoprotective effect of dexmedetomidine (Dex) in vitro. Cultured HK2 cell injury was provoked with culture media deprived of
oxygen and glucose (OGD). (A) The time course of OGD. (B) The dose response of Dex (0.001 to 0.1 nM) against OGD induced injury in the
presence or absence of a2 adrenoceptor antagonist, atipamazole (Atip) (1 nM). Data are expressed as mean ± SD (n = 5). *P < 0.05; **P < 0.01 vs
zero time point or control.
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cells (HK2) cells were treated with dexmedetomidine and the time course of phospho-a serine/threonine protein kinase (pAkt) expression in
culture homogenised supernatant was assessed with western blot (A) and its effect was abolished with the highly selective inhibitor of PI3-Akt,
LY294002 (LY) (50 μM), but not by a2 adrenoceptor antagonist, atipamazole (Atip) (1 nM) and mitogen-activated protein kinase (MAPK), PD98059
(PD) (50 μM) (B). Data are expressed as the percentage of control (mean ± SD; n = 4). *P < 0.05; **P < 0.01 vs control; +P < 0.05; ++P < 0.01 vs
Dex.
Figure 3 In vivo renoprotection by dexmedetomidine (Dex) vs renal ischemia-reperfusion injury (IRI)-histology. Adult male mice were
pretreated or post-treated with dexmedetomidine alone or in combination with a2 adrenoceptor antagonist, atipamazole (Atip) (1 nM) followed
by clamping of the bilateral renal pedicle for 25 minutes. Reno-protection of Dex was assessed histologically (H&E staining). Representative
microphotographs were taken from a naïve control (A), Dex alone (B), IRI alone (C), pre-Dex treatment (25 μ/kg) +IRI (D), post-Dex treatment (25
microgm/kg) + IRI (E) and Atip + pre-Dex+IRI (F). (G) Quantification of histological scoring following IRI in mice pretreated as above. Bar = 100
μm. Data are mean ± SD (n = 5). **P < 0.01 vs control. ++P < 0.01 vs IRI.
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dexmedetomidine was given to mice not subjected to renal
injury (8.0 ± 2.3; NS versus naïve controls).
A similar pattern of changes were noted in renal func-
tion. After IRI, the plasma creatinine rose from 34.6 ±
2.2 to 81.8 ± 6.4 μM/L. Pre-treatment with dexmedeto-
midine was protective, with creatinine showing no sig-
nificant difference from animals not subjected to renal
injury. When dexmedetomidine pre-treatment was pre-
ceded by atipamazole, this abrogated the protective
effect so that creatinine was significantly higher (85.8 ±
37.8; P < 0.01) than that seen in the uninjured animals
(Figure 5A). Similarly, IRI-induced increase in plasma
urea (from 5.4 ± 0.2 to 27.9 ± 5.0 mM/L) was signifi-
cantly reduced following pre-treatment with dexmedeto-
midine (18.22 ± 4.3; P < 0.05), an effect that was
completed abolished by atipamazole (30.0 ± 4.7; P <
0.01) (Figure 5B).
Dexmedetomidine attenuates Toll-like Receptor 4 (TLR4)
expression in tubular cells
To investigate the molecular mechanisms of dexmedeto-
midine-induced renoprotection, we assessed toll-like
receptor 4 (TLR4) expression in situ and its upstream
mediator, high mobility group box-1 (HMGB1) nuclear
protein in plasma. HMGB1 and TLR4 signaling play a
pivotal role in the coordination of inflammatory responses
in renal IRI [30,31]. There was no detectable staining when
primary antibody was omitted (data not shown) while
TLR4 expression was at very minimal level in the naïve
control (Figure 6A). However, marked increases in renal
TLR4 expression were detected in IRI mice using in situ
immunostaining (Figure 6B) and Western blot (Figure 6E).
Pre-treatment with dexmedetomidine resulted in a dra-
matic decrease in TLR4 expression (Figure 6C) to a level
even lower than that of control (Figure 6E), which was
effectively restored to even the higher level than that in the
Figure 4 In vivo reno-protection afforded by dexmedetomidine (Dex) vs renal ischemia-reperfusion injury (IRI)- TUNEL staining. Adult
male mice were pretreated or post-treated with Dex alone or in combination with a2 adrenoceptor antagonist, atipamazole (Atip) (1 nM)
followed by clamping the bilateral renal pedicle for 25 minutes and the renoprotection of Dex was assessed with terminal deoxynucleotidyl
transferase dUTP nick end (TUNEL) staining. Representative microphotographs taken from a naïve control (A), Dex alone (B), IRI alone (C), pre-
Dex treatment (25 μg/kg) +IRI (D), post-Dex treatment (25 μg/kg) + IRI (E) and Atip + pre-Dex+IRI (F). (G) Quantification of TUNEL positive cell
counting following IRI in mice pretreated as above. Bar = 100 μm. Data are mean ± SD (n = 5 to 6). *P < 0.05, **P < 0.01 vs control. ++P < 0.01
vs IRI.
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HMGB1 levels were dramatically elevated in IRI mice
(from 25.9 ± 2.9 to 122.4 ± 40.3 pg/ml; P < 0.001), com-
pared to control. Pre- and post-treatment with dexmedeto-
midine significantly attenuated the rise in HMGB1 (58.1 ±
19.5 and 61.5 ± 28.3; both P < .01) compared to IRI mice,
respectively (Figure 6F). The protective effects of dexmede-
tomidine pre-treatment on HMGB1 upregulation were
partially inhibited by atipamazole (61.5 ± 28.3; P <0 . 0 5 )
relative to IRI mice. Together, these findings suggest that
Figure 5 In vivo renoprotection afforded by dexmedetomidine (Dex) vs renal ischemia-reperfusion injury (IRI). Adult male Mice were
pretreated or post-treated with Dex alone or in combination with a2 adrenoceptor antagonist, atipamazole (Atip) (1 nM) and the renoprotection
of Dex was assessed with plasma creatinine (A) and urea measurement (B). Data are mean ± SD (n = 5 to 6). * P < 0.05, **P < 0.01 vs control.
+P < 0.05, ++P < 0.01 vs IRI.
Figure 6 Anti-inflammatory effect afforded by dexmedetomidine (Dex) in vivo. Toll-like receptor 4 (TLR4) expression was assessed with in
situ immunostaining and Western blot. Naïve control (A); Renal ischemia-reperfusion injury (IRI) (B); Dex+IRI (C); Atip (atipamazole) + pre-Dex+IRI
(D) and Western blot (E). (F) Plasma level of High-mobility group protein B1 (HMGB1). Bar = 100 μm. Data are mean ± SD (n = 4). **P < 0.01 vs
control. +P < 0.05, ++P < 0.01 vs IRI.
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may be partially dependent on an a2 adrenoceptor-
mediated mechanism. No change was seen in naïve mice
treated with dexmedetomidine.
Dexmedetomidine protects from renal failure
To assess whether dexmedetomidine was also effective
in the context of a more severe insult to renal function,
we performed additional experiments in which the right
renal pedicle was clamped for 40 minutes and the left
kidney was removed. The mean value of plasma creati-
nine and urea rose more than seven-fold at 24 h after
IRI (to 233.5 ± 34.1 μM/L and 62.1 ± 10.2 mM/L,
respectively). Administration of dexmedetomidine either
before or after IRI significantly attenuated the rise in
creatinine and urea values (both P < 0.01) relative to IRI
controls (Figure 7A, B). Atipamezole treatment did not
change creatinine and urea in IRI mice but significantly
inhibited the renal protective effects of dexmedetomi-
dine (P < 0.001, all comparisons). Long-term survival
(no signs of illness at seven days) was noted in 70% and
60% of animals treated with dexmedetomidine before
and after renal IRI. By contrast, animals not treated with
dexmedetomidine or receiving atipamezole combined
dexmedetomidine fared much worse. Within three days,
65% of these animals were dead (either spontaneously
or killed because of severe ill health measured against
previously reported predefined criteria [28] and no ani-
mals survived beyond five days after IRI (P <0 . 0 0 1v e r -
sus pre- and post-dexmedetomidine groups; Figure 7C).
Discussion
Our work showed that dexmedetomidine induced a sus-
tained up-regulation of phospho-Akt and protected
against oxygen-glucose deprivation in a human kidney
cell line; its effects were blocked by atipamezole. In vivo,
Figure 7 Renal failure induced by ischemia-reperfusion prevented by dexmedetomidine (Dex). Mice received Dex before or after IRI and
kidney injury was induced by clamping the right renal pedicle for 40 minutes while the contralateral kidney was removed. The animals were
allowed for 24 hrs before functional measurements (A - Creatinine; B - Urea), or up to seven days for the long term Kaplan-Meier survival curve
analysis (n = 10) (C). Atip = atipamazole; IRI = Ischemia reperfusion injury. Data are mean ± SD (n = 5). **P < 0.01 vs control. +P < 0.05, ++P <
0.01 vs IRI.
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way, preserving tubular architecture and reducing cell
death. Associated with the improved histological find-
ings, the level of renal dysfunction was minimized and
renal failure was prevented after severe IRI resulting in
improved survival. The organ-protective effect was abol-
ished with a2 adrenoreceptor antagonist, indicating that
dexmedetomidine acted in an a2 adrenoreceptor depen-
dent manner.
Our data demonstrated a significantly increased
expression of phospho-Akt in cultured tubular cells
after treatment with dexmedetomidine (Figure 2). This
was blocked partially by an a2 adrenoceptor antagonist
and significantly reduced by a PI3K inhibitor, indicating
that the dexmedetomidine activates Akt via both a2
adrenoceptor dependent and independent-PI3K cou-
pling. In summation, we consider it likely that the acti-
vation of PI3K-Akt is one of the survival cascades
activated by dexmedetomidine to induce cytoprotection
(Figure 1). The PI3K-Akt pathway promotes cell survival
by phosphorylating the proapoptotic Bcl-2-associated
death promotor (BAD) and up-regulating the expression
of anti-apoptotic Bcl-2 and Bcl-xl [32], inhibiting the
caspase-controlled intrinsic apoptotic pathway [33].
Consistent with our findings, dexmedetomidine has
been shown to decrease the expression of pro-apoptotic
factors such as caspase-3 [34] and Bax whilst increasing
the expression of anti-apoptotic Bcl-2 and Mdm-2 [35]
in the brain. Akt signaling has previously been shown to
be critical to recovery from renal IRI injury and there-
fore, it can be concluded that dexmedetomidine protec-
tion may involve Akt signaling.
In addition to its cytoprotective effects, our studies
demonstrated that dexmedetomidine suppressed the
TLR-4 mediated inflammatory circuitry. Expression of
TLR-4 has been shown to be triggered through endo-
genous ligands, including damage-associated molecular
patterns (DAMPs) and cytokines. High mobility group
box 1 (HMGB-1) is a potent DAMP released from dying
cells during tissue ischemia. It binds to TLR-4 initiating
down-stream NF-B signaling cascade [36] substantially
augmenting the synthesis of pro-inflammatory cytokines
such as TNF-a and IL-1b [37]. Recent work by Wu et
al., [38] demonstrated that TLR4-deficient or the adap-
tor molecule myD88-deficient mice were protected from
both kidney dysfunction and histological damage
induced by renal IRI. Generation of pro-inflammatory
cytokine (IL-6, IL-1b,a n dT N F - a) and chemokines
(MIP-2 and MCP-1) was inhibited, together with a par-
allel decline of macrophage and neutrophil infiltration.
Pre-treatment of dexmedetomine resulted in almost
complete attenuation of TLR-4 expression associated
with decreased cell death of tubular epithelial cells. We
propose that dexmedetomidine may have prevented the
increased expression of TLR-4 by attenuating tissue
injury (evidenced by lower systemic HMGB1 levels and
reduced TUNEL staining) and through co-existent anti-
inflammatory actions [39-41] (Figure 8). Herein, we did
not further explore the well described anti-inflammatory
effects of dexmedetomidine (beyond HMGB1 levels);
however, dexmedetomidine reduces systemic levels of
IL-6 and TNF-a following lipopolysaccharide infusion in
rats [39] and following cardiac surgery [40] and sepsis in
humans [42]. It is, therefore, plausible that the anti-
inflammatory actions of dexmedetomidine contributed
to the reduced TLR-4 expression following renal
ischemia.
Figure 8 Putative mechanism of dexmedetomidine (Dex)
renoprotection. Dexmedetomidine stimulates the a2 adrenoceptor
(a2) to induce phosphoinositol-3-kinase (PI3K) phosphorylation of
Akt (pAKT) and activation of the downstream cell survival signaling
to block ischemia induced injury. Ischemia is denoted by the “flash”
symbol. Improved cellular survival leads to reduced release of the
damage-associated molecular pattern High-mobility group protein
B1 (HMGB1). Reduced HMGB1 decreases the inflammatory drive that
both increases Toll-like receptor 4 (TLR4) expression and activates
the detrimental effect of TLR4 signaling in renal ischemia. Co-
receptors for HMGB1 include TLRs and Interleukin-1 (IL-1) receptor;
when HMGB1 binds to the ligand (for example, lipopolysaccharide
or IL-1) this augments subsequent proinflammatory signaling.
Therefore, dexmedetomidine acts proximally in the pathway (at the
cytoprotective level) to prevent the elaboration of renal ischemic
injury. ‘Lightening bolt’ denotes ischemia. ‘Square’ denotes HMGB1
co-receptor.
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Page 9 of 11Our study showed a marked improvement in renal
morphology and function with reduced nitrogenous
waste accumulation following treatment of dexmedeto-
midine. This protection was attenuated by atipamezole,
an a2 adrenoreceptor antagonist, confirming depen-
dence on a2-adrenoceptor agonism. Similarly dexmede-
tomidine’s neuroprotective effect is mediated by a2-
adrenoceptor signaling [19]. Consistent with evidence
from neuroprotection, our in vitro data suggest that the
primary effect of dexmedetomidine is cytoprotection;
nonetheless, in vivo it is likely that improved renal
blood flow may have contributed to improved renal
function and recovery from ischemia. Indeed modula-
tion of vasoreactivity, through reduced sympathetic
drive, has been shown to be an important mechanism of
a2 adrenoceptor agonist renoprotection [21,24,25]. In a
model of radiocontrast nephropathy a2-adrenoceptor
activation with dexmedetomidine resulted in improved
renal function, an effect attributable to improved renal
blood flow [21]. However, a2-adrenoceptor activation
was not associated with cytoprotection from radiocon-
trast exposure in vitro [21] indicating that there are dif-
fering mechanisms of radiocontrast and ischemic injury
in the kidney. The local responses to a2-adrenoceptor
activation in the kidney include vasodilatation [21], inhi-
bition of renin release, increased glomerular filtration
and increased secretion of sodium and water [43,44].
a2-adrenoceptor agonists may preserve glomerular filtra-
tion by preventing reduced renal blood flow following
reperfusion associated vasospasm. They may also pro-
voke diuresis by opposing the activity of arginine vaso-
pressin in the collecting duct as well reducing aquaporin
expression [45]. In combination, cytoprotection,
improved glomerular filtration and diuretic actions may
have improved renal function following ischemic injury.
a2-adrenoceptor agonists have diverse utility in the
perioperative period; their renoprotective qualities are
complemented by their analgesic qualities that reduce
the necessity of other analgesics. Reduced use of non-
steroidal anti-inflammatory drugs and opioids may be
of particular interest as non-steroidal anti-inflamma-
tory drugs increase the risk of AKI and opioids accu-
mulate in AKI. Furthermore, the hemodynamic
control, cardioprotection and mild diuretic properties
of a2-adrenoceptor agonists may indirectly support
renal function. We consider there are multiple reasons
to consider a large prospective randomized controlled
trial of the reno-protective qualities of a2-adrenoceptor
agonists.
Conclusions
AKI associated with ischemia-reperfusion injury is a sig-
nificant contributor to morbidity and mortality in the
perioperative period. dexmedetomidine provides
renoprotection against renal IRI whether given as a pro-
phylactic or therapeutic measure. Our data complement
preliminary clinical data showing that prophylactic clo-
nidine treatment prevented renal dysfunction attributa-
ble to cardiac surgery and that dexmedetomidine
improved renal function following thoracic surgery. If
our data can be extrapolated to clinical settings, dexme-
detomidine may prove protective against IRI associated
acute renal failure.
Key messages
￿ Acute kidney injury following surgery significantly
increases mortality with no proven preventative
therapy.
￿ The a2 adrenoceptor agonist dexmedetomidine has
organoprotective properties.
￿ Dexmedetomidine activates cell survival signal
pAKT via a2 adrenoceptors to reduce cell death and
HMGB1 release and subsequently inhibits TLR4 sig-
naling to provide renoprotection.
￿ Dexmedetomidine may have both cytoprotective
and anti-inflammatory effects to protect against
renal injury following ischemia-reperfusion.
￿ If our data can be extrapolated to clinical settings,
dexmedetomidine may prove protective against IRI
associated acute renal failure.
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